Herantis Pharma Oyj (HEL:HRTIS)
Finland
· Delayed Price · Currency is EUR 1.355
-0.030 (-2.17%)
May 12, 2025, 6:12 PM EET
Herantis Pharma Oyj Company Description
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD).
The company’s lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases.
The company was incorporated in 2008 and is based in Espoo, Finland.
Herantis Pharma Oyj
| Country | Finland |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Antti Vuolanto |
Contact Details
Address: Bertel Jungin Aukio 1 Espoo, 02600 Finland | |
| Phone | 358 9222 1195 |
| Website | herantis.com |
Stock Details
| Ticker Symbol | HRTIS |
| Exchange | Nasdaq Helsinki |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FI4000087861 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Antti Vuolanto D.Sc. (Tech) | Chief Executive Officer |
| Tone Kvale | Chief Financial Officer |
| Dr. Henri J. Huttunen Ph.D. | Chief Scientific Officer |
| Jani Koskinen | Head of CMC |
| Dr. Charlotte Videbaek M.D. | Clinical Consultant |